208 related articles for article (PubMed ID: 35928274)
1. How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries.
Blonda A; Denier Y; Huys I; Kawalec P; Simoens S
Front Pharmacol; 2022; 13():902150. PubMed ID: 35928274
[No Abstract] [Full Text] [Related]
2. How to Value Orphan Drugs? A Review of European Value Assessment Frameworks.
Blonda A; Denier Y; Huys I; Simoens S
Front Pharmacol; 2021; 12():631527. PubMed ID: 34054519
[No Abstract] [Full Text] [Related]
3. Reimbursement of orphan drugs in Belgium: what (else) matters?
Picavet E; Cassiman D; Simoens S
Orphanet J Rare Dis; 2014 Sep; 9():139. PubMed ID: 25208770
[TBL] [Abstract][Full Text] [Related]
4. Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries.
Blonda A; Barcina Lacosta T; Toumi M; Simoens S
Front Pharmacol; 2021; 12():750742. PubMed ID: 35126102
[No Abstract] [Full Text] [Related]
5. Development of the Emirates Multi-Criteria Decision Analysis Tool for Orphan Drugs.
Alnaqbi KA; Elezbawy B; Fasseeh AN; Bangash AR; Elshamy A; Shendi H; Aftab MI; AlMarshoodi M; Gebran N; AlDhaheri N; Fahmy SA; Al Dallal S; Al Naeem W; Abaza S; Kaló Z
Cureus; 2024 Feb; 16(2):e55215. PubMed ID: 38558740
[TBL] [Abstract][Full Text] [Related]
6. Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries.
Jakubowski S; Kawalec P; Holko P; Kowalska-Bobko I; Kamusheva M; Petrova G; Draganić P; Fuksa L; Männik A; Ispán F; Briedis V; Bianchi I; Paveliu MS; Tesar T
Front Pharmacol; 2024; 15():1369178. PubMed ID: 38523639
[No Abstract] [Full Text] [Related]
7. Multi-Criteria Decision Analysis for Assessment and Appraisal of Orphan Drugs.
Iskrov G; Miteva-Katrandzhieva T; Stefanov R
Front Public Health; 2016; 4():214. PubMed ID: 27747207
[TBL] [Abstract][Full Text] [Related]
8. Insight into reimbursement decision-making criteria in Bulgaria: implications for orphan drugs.
Iskrov GG; Raycheva RD; Stefanov RS
Folia Med (Plovdiv); 2013; 55(3-4):80-6. PubMed ID: 24712287
[TBL] [Abstract][Full Text] [Related]
9. [Authorization and reimbursement of orphan drugs in an international comparison].
Roll K; Stargardt T; Schreyögg J
Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
[TBL] [Abstract][Full Text] [Related]
10. Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European Countries.
Nicod E; Berg Brigham K; Durand-Zaleski I; Kanavos P
Value Health; 2017; 20(7):919-926. PubMed ID: 28712621
[TBL] [Abstract][Full Text] [Related]
11. What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries.
Maynou L; Cairns J
Health Policy; 2019 Feb; 123(2):130-139. PubMed ID: 30477736
[TBL] [Abstract][Full Text] [Related]
12. The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe.
Kawalec P; Sagan A; Pilc A
Orphanet J Rare Dis; 2016 Sep; 11(1):122. PubMed ID: 27600717
[TBL] [Abstract][Full Text] [Related]
13. Critical assessment of belgian reimbursement dossiers of orphan drugs.
Denis A; Mergaert L; Fostier C; Cleemput I; Hulstaert F; Simoens S
Pharmacoeconomics; 2011 Oct; 29(10):883-93. PubMed ID: 21905759
[TBL] [Abstract][Full Text] [Related]
14. Novel approach to decision making for orphan drugs.
Decker B; Mlcoch T; Pustovalova A; Dolezal T
Int J Technol Assess Health Care; 2023 Feb; 39(1):e10. PubMed ID: 36748356
[TBL] [Abstract][Full Text] [Related]
15. Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries.
Malinowski KP; Kawalec P; Trąbka W; Czech M; Petrova G; Manova M; Savova A; Draganić P; Vostalová L; Slabý J; Männik A; Márky K; Rugaja Z; Gulbinovic J; Tesar T; Paveliu MS
Front Pharmacol; 2019; 10():487. PubMed ID: 31139080
[TBL] [Abstract][Full Text] [Related]
16. Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework.
Paulden M; Stafinski T; Menon D; McCabe C
Pharmacoeconomics; 2015 Mar; 33(3):255-69. PubMed ID: 25412735
[TBL] [Abstract][Full Text] [Related]
17. Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment.
Malinowski KP; Kawalec P; Trabka W; Sowada C; Pilc A
Front Pharmacol; 2018; 9():1263. PubMed ID: 30483124
[No Abstract] [Full Text] [Related]
18. The Development of the Romanian Scorecard HTA System.
Radu CP; Chiriac ND; Pravat AM
Value Health Reg Issues; 2016 Sep; 10():41-47. PubMed ID: 27881276
[TBL] [Abstract][Full Text] [Related]
19. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
Zelei T; Molnár MJ; Szegedi M; Kaló Z
Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
[TBL] [Abstract][Full Text] [Related]
20. Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut).
Guarga L; Badia X; Obach M; Fontanet M; Prat A; Vallano A; Torrent J; Pontes C
Orphanet J Rare Dis; 2019 Jun; 14(1):157. PubMed ID: 31248421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]